Arcellx (ACLX) Current Deferred Revenue (2021 - 2025)
Arcellx (ACLX) recorded quarterly Current Deferred Revenue of $56.0 million in Q4 2025, down 6.33% quarter-over-quarter from $59.8 million in Q3 2025, and down 58.56% on a YoY basis from $135.1 million in Q4 2024.
Arcellx (ACLX) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Arcellx's Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $56.0 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 58.56% year-over-year to $56.0 million; the TTM figure through Dec 2025 stood at $56.0 million (down 58.56% YoY), while the FY2025 annual figure was $56.0 million, down 58.56% from the prior year.
- Current Deferred Revenue was $56.0 million for Q4 2025 at Arcellx, down from $59.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $221.2 million in Q4 2023 to a low of $183000.0 in Q4 2021.
- Historically, Current Deferred Revenue has averaged $76.9 million across 4 years, with a median of $59.8 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue sank 84.05% in 2024, then soared 296.27% in 2025.
- A 4-year view of Current Deferred Revenue shows it stood at $183000.0 in 2021, then soared by 120777.6% to $221.2 million in 2023, then tumbled by 38.95% to $135.1 million in 2024, then plunged by 58.56% to $56.0 million in 2025.
- The last three Current Deferred Revenue figures came in at $56.0 million (Q4 2025), $59.8 million (Q3 2025), and $59.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 55.97 Mn |
| Sep 30, 2025 | 59.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | 57.37 Mn |
| Dec 31, 2024 | 135.05 Mn |
| Sep 30, 2024 | 69.87 Mn |
| Jun 30, 2024 | 14.97 Mn |
| Mar 31, 2024 | 31.19 Mn |
| Dec 31, 2023 | 221.21 Mn |
| Sep 30, 2023 | 94.18 Mn |
| Jun 30, 2023 | 93.88 Mn |
| Mar 31, 2023 | 107.29 Mn |
| Dec 31, 2021 | 183,000.00 |